A Phase 3 interventional study of Cabergoline and Placebo in Restless Legs Syndrome, sponsored by Pfizer. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-25.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS. Also, additional objective and subjective sleep parameters and quality of life will be assessed.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
This study's enrollment of 43 is below the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Browse Restless Legs Syndrome studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Cabergoline
Other: Placebo
Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
Placebo oral tablets administered daily for 5 weeks
Sleep efficiency
Time frame: Week 5
PLMS-arousal index (PLMS-AI)
Time frame: Week 5
Sleep Questionnaire Form A
Time frame: Weeks 2 and 5
Quality of Life for RLS questionnaire
Time frame: Weeks 2 and 5
Clinical Global Impressions
Time frame: Weeks 2 and 5
Safety including type and frequency of adverse events, changes in laboratory data and abnormalities observed in electrocardiography
Time frame: Weeks 2 and 5
Total score of the severity rating scale of the International RLS (IRLS) Study Group
Time frame: Weeks 2 and 5
RLS-6 severity scales
Time frame: Weeks 2 and 5
No study locations are listed for this record.
The record gives a start of Nov 2002 and a completion of May 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabergoline